Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis.
Anti-neutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3) are strongly associated with Wegener's granulomatosis (WG) and are thought to be involved in its pathogenesis. Levels of PR3-ANCA do not always correspond to clinical disease activity. To investigate the relationship between functional effects of PR3-ANCA and disease activity, we tested the effect of IgG samples from sera of 43 WG patients, taken during active disease or remission, for their capacity to interfere with the proteolytic activity of PR3. Furthermore, longitudinal sera of seven WG patients were included. The enzymatic activity of PR3 was determined (1) with casein or with a small synthetic substrate and (2) by complexation of PR3 with alpha1-antitrypsin (alpha1-AT). With a fixed concentration (100 microg/ml) of IgG, PR3-ANCA from patients during an active phase of WG had a higher inhibitory capacity towards the proteolytic activity of PR3 and complexation of PR3 with alpha1-AT than did PR3-ANCA from WG patients during remission. However, the number of PR3-ANCA units that gave 50% inhibition of the PR3 enzymatic activity and its complexation with alpha1-AT was lower for patients during remission than for patients during an active phase of WG, indicating a stronger inhibitory capacity at a molar base. In conclusion, PR3-ANCA from patients during remission had a relatively higher inhibitory capacity towards the enzymatic activity of PR3 than PR3-ANCA from patients during an active phase. This may indicate that during active disease the ANCA titre is increased, but the number of active ANCA molecules that recognize the enzyme-inhibiting epitopes is not increased.
van der Geld
Y M
YM
Department of Internal Medicine, University Hospital Groningen, The Netherlands.
Tool
A T J
AT
Videler
J
J
de Haas
M
M
Tervaert
J W Cohen
JW
Stegeman
C A
CA
Limburg
P C
PC
Kallenberg
C G M
CG
Roos
D
D
D000328:Adult; D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood / Q000494:pharmacology*; D002364:Caseins / Q000378:metabolism; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis / Q000201:enzymology* / Q000276:immunology*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D053146:Myeloblastin; D009842:Oligopeptides / Q000378:metabolism; D012008:Recurrence; D012075:Remission, Spontaneous; D012697:Serine Endopeptidases / Q000276:immunology* / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000097:blood / Q000494:pharmacology; D000515:alpha 1-Antitrypsin / Q000378:metabolism
D019268:Antibodies, Antineutrophil Cytoplasmic; D002364:Caseins; D009842:Oligopeptides; D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin; C067253:N-methoxysuccinyl-alanyl-alanyl-prolyl-valine-4-nitroanilide; D012697:Serine Endopeptidases; D053146:Myeloblastin